Table 6. Differences among imaging findings, laboratory examinations, and responses to treatment between acute Q fever patients whose sera were positive and negative for Mycoplasma pneumoniae IgMa.
| Clinical characteristics | Negative for M. pneumoniae IgM (N=43) | Positive for M. pneumoniae IgM (N=59) | Total (N=102) | p b |
|---|---|---|---|---|
| Abdominal sonography or computed tomography findings | 39 (90.7) | 56 (94.9) | 0.451 | |
| Days from disease onsetc | 6.8 ± 4.0 | 7.0 ± 3.3 | 6.9 ± 3.6 | 0.778 |
| Abnormal | 18/39 (46.2) | 25/56 (44.6) | 43/95 (45.3) | 0.999 |
| Hepatomegaly or splenomegaly | 15 (38.5) | 18 (32.1) | 33/95 (34.7) | 0.662 |
| Hepatomegaly | 9/39 (23.1) | 13/56 (23.2) | 22/95 (23.2) | 0.999 |
| Splenomegaly | 12/39 (30.8) | 10/56 (17.9) | 22/95 (23.2) | 0.216 |
| Cholecystitic change | 6/39 (15.4) | 17/56 (30.4) | 23/95 (24.2) | 0.143 |
| Fatty liver | 22/39 (56.4) | 28/56 (50.0) | 50/95 (52.6) | 0.676 |
| Chest x-ray | ||||
| Days from disease onsetc | 5.3 ± 3.1 | 5.7 ± 2.7 | 5.5 ± 2.9 | 0.519 |
| Abnormal CXR finding | 4/42 (9.5) | 11/57 (19.3) | 16/99 (15.2) | 0.258 |
| Unilateral infiltration | 2/42 (4.8) | 5/57 (8.8) | 7/99 (7.1) | 0.695 |
| Bilateral infiltration | 2/42 (4.8) | 6/57 (10.5) | 8/99 (8.1) | 0.461 |
| Pneumonia patch | 0/42 (0) | 0/57 (0) | 0/99 (0) | NC |
| Complete blood cell examination | ||||
| Days from disease onsetc | 5.1 ± 3.1 | 5.3 ± 2.5 | 5.2 ± 2.7 | 0.813 |
| Leukocytosis | 2 (4.7) | 2 (3.4) | 4/102 (3.9) | 0.999 |
| Leukopenia | 9 (20.9) | 7 (11.9) | 16/102 (15.7) | 0.273 |
| Anemia | 0 (0) | 0 (0) | 0/102 (0) | NC |
| Thrombocytopenia | 30 (69.8) | 43 (72.9) | 73/102 (71.6) | 0.825 |
| Liver transaminase | ||||
| Days from disease onsetc | 5.6 ± 3.9 | 5.7 ± 2.6 | 5.6 ± 3.2 | 0.849 |
| GPT > 88 | 23/42 (54.8) | 42/59 (71.2) | 65/101 (64.4) | 0.097 |
| GOT > 76 | 27/42 (64.3) | 43/58 (74.1) | 70/100 (70.0) | 0.377 |
| GPT > 44 | 40/42 (95.2) | 58/59 (98.3) | 98/101 (97.0) | 0.569 |
| GOT > 38 | 41/42 (97.6) | 57/58 (98.3) | 98/100 (98.0) | 0.999 |
| Doxycycline treatment to defervescence > 3 days | 5/35 (14.3) | 10/44 (22.7) | 15/79 (19.0) | 0.398 |
a
Tested by ELISA (NovaTec Immundiagnostica GmbH, Germany).
b
Categorical variables were analyzed using the Chi-square or Fisher’s exact test as appropriate. Continuous variables were analyzed using Student’s t-test.
c
Presented as the mean value ± standard deviation.